Identification of the cytochrome P450 enzymes responsible for the ω-hydroxylation of phytanic acid

FEBS Letters

Volumn 580, Issue 16, 2006, Pages 3794-3798

  Komen, J C ^a   Wanders, R J A ^a  

^a EMMA CHILDREN S HOSPITAL   (Netherlands)

Author keywords

Hydroxylation; Oxidation; Branched chain fatty acid; Cytochrome P450; Phytanic acid; Refsum disease

Indexed keywords

CYTOCHROME P450; CYTOCHROME P450 4A11; CYTOCHROME P450 4F2; CYTOCHROME P450 4F3A; CYTOCHROME P450 4F3B; PHYTANIC ACID; RECOMBINANT ENZYME; UNCLASSIFIED DRUG;

ARTICLE; CONTROLLED STUDY; ENZYME ANALYSIS; HUMAN; HUMAN CELL; HYDROXYLATION; INCUBATION TIME; MICROSOME; PRIORITY JOURNAL; PROTEIN FAMILY;

CYTOCHROME P-450 ENZYME SYSTEM; DITIOCARB; FATTY ACIDS, UNSATURATED; HUMANS; HYDROXYLATION; KINETICS; MICROSOMES, LIVER; PHYTANIC ACID; RECOMBINANT PROTEINS;

EID: 33745395168     PISSN: 00145793     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.febslet.2006.05.069     Document Type: Article

References (33)

1. Mukherji M., Schofield C.J., Wierzbicki A.S., Jansen G.A., Wanders R.J., and Lloyd M.D. The chemical biology of branched-chain lipid metabolism. Prog. Lipid Res. 42 (2003) 359-376
2. Jansen G.A., Ofman R., Ferdinandusse S., Ijlst L., Muijsers A.O., Skjeldal O.H., Stokke O., Jakobs C., Besley G.T., Wraith J.E., and Wanders R.J. Refsum disease is caused by mutations in the phytanoyl-CoA hydroxylase gene. Nat. Genet. 17 (1997) 190-193
3. Mihalik S.J., Morrell J.C., Kim D., Sacksteder K.A., Watkins P.A., and Gould S.J. Identification of PAHX, a Refsum disease gene. Nat. Genet. 17 (1997) 185-189
4. van den Brink D.M., Brites P., Haasjes J., Wierzbicki A.S., Mitchell J., Lambert-Hamill M., de Belleroche J., Jansen G.A., Waterham H.R., and Wanders R.J. Identification of PEX7 as the second gene involved in Refsum disease. Am. J. Hum. Genet. 72 (2003) 471-477
5. Wierzbicki A.S., Lloyd M.D., Schofield C.J., Feher M.D., and Gibberd F.B. Refsum's disease: a peroxisomal disorder affecting phytanic acid alpha-oxidation. J. Neurochem. 80 (2002) 727-735
6. Okita R.T., and Okita J.R. Cytochrome P450 4A fatty acid omega hydroxylases. Curr. Drug Metab. 2 (2001) 265-281
7. Simpson A.E. The cytochrome P450 4 (CYP4) family. Gen. Pharmacol. 28 (1997) 351-359
8. Sanders R.J., Ofman R., Valianpour F., Kemp S., and Wanders R.J. Evidence for two enzymatic pathways for {omega}-oxidation of docosanoic acid in rat liver microsomes. J. Lipid Res. 46 (2005) 1001-1008
9. Billimoria J.D., Clemens M.E., Gibberd F.B., and Whitelaw M.N. Metabolism of phytanic acid in Refsum's disease. Lancet 1 (1982) 194-196
10. Wierzbicki A.S., Mayne P.D., Lloyd M.D., Burston D., Mei G., Sidey M.C., Feher M.D., and Gibberd F.B. Metabolism of phytanic acid and 3-methyl-adipic acid excretion in patients with adult Refsum disease. J. Lipid Res. 44 (2003) 1481-1488
11. Greter J., Lindstedt S., and Steen G. 2,6-Dimethyloctanedioic acid-a metabolite of phytanic acid in Refsum's disease. Clin. Chem. 29 (1983) 434-437
12. Komen J.C., Duran M., and Wanders R.J. Omega-hydroxylation of phytanic acid in rat liver microsomes: implications for Refsum disease. J. Lipid Res. 45 (2004) 1341-1346
13. Komen J.C., Duran M., and Wanders R.J. Characterization of phytanic acid omega-hydroxylation in human liver microsomes. Mol. Genet. Metab. 85 (2005) 190-195
14. Waxman D.J. P450 gene induction by structurally diverse xenochemicals: central role of nuclear receptors CAR, PXR, and PPAR. Arch. Biochem. Biophys. 369 (1999) 11-23
15. Honkakoski P., and Negishi M. Regulation of cytochrome P450 (CYP) genes by nuclear receptors. Biochem. J. 347 (2000) 321-337
16. Eagling V.A., Tjia J.F., and Back D.J. Differential selectivity of cytochrome P450 inhibitors against probe substrates in human and rat liver microsomes. Br. J. Clin. Pharmacol. 45 (1998) 107-114
17. Wen X., Wang J.S., Backman J.T., Laitila J., and Neuvonen P.J. Trimethoprim and sulfamethoxazole are selective inhibitors of CYP2C8 and CYP2C9, respectively. Drug Metab. Dispos. 30 (2002) 631-635
18. Newton D.J., Wang R.W., and Lu A.Y. Cytochrome P450 inhibitors. Evaluation of specificities in the in vitrometabolism of therapeutic agents by human liver microsomes. Drug Metab. Dispos. 23 (1995) 154-158
19. Ko J.W., Sukhova N., Thacker D., Chen P., and Flockhart D.A. Evaluation of omeprazole and lansoprazole as inhibitors of cytochrome P450 isoforms. Drug Metab. Dispos. 25 (1997) 853-862
20. Baldwin S.J., Bloomer J.C., Smith G.J., Ayrton A.D., Clarke S.E., and Chenery R.J. Ketoconazole and sulphaphenazole as the respective selective inhibitors of P4503A and 2C9. Xenobiotica 25 (1995) 261-270
21. Chang T.K., Gonzalez F.J., and Waxman D.J. Evaluation of triacetyloleandomycin, alpha-naphthoflavone and diethyldithiocarbamate as selective chemical probes for inhibition of human cytochromes P450. Arch. Biochem. Biophys. 311 (1994) 437-442
22. Guengerich F.P., and Shimada T. Oxidation of toxic and carcinogenic chemicals by human cytochrome P-450 enzymes. Chem. Res. Toxicol. 4 (1991) 391-407
23. Zou A.P., Ma Y.H., Sui Z.H., Ortiz de Montellano P.R., Clark J.E., Masters B.S., and Roman R.J. Effects of 17-octadecynoic acid, a suicide-substrate inhibitor of cytochrome P450 fatty acid omega-hydroxylase, on renal function in rats. J. Pharmacol. Exp. Ther. 268 (1994) 474-481
24. Shak S., Reich N.O., Goldstein I.M., and Ortiz de Montellano P.R. Leukotriene B4 omega-hydroxylase in human polymorphonuclear leukocytes. Suicidal inactivation by acetylenic fatty acids. J. Biol. Chem. 260 (1985) 13023-13028
25. Kikuta Y., Kusunose E., and Kusunose M. Prostaglandin and leukotriene omega-hydroxylases. Prostagl. Other Lipid Mediat. 68-69 (2002) 345-362
26. Kroetz D.L., and Xu F. Regulation and inhibition of arachidonic acid-hydroxylases and 20-HETE formation. Annu. Rev. Pharmacol. Toxicol. 45 (2005) 413-438
27. Christmas P., Ursino S.R., Fox J.W., and Soberman R.J. Expression of the CYP4F3 gene. tissue-specific splicing and alternative promoters generate high and low K(m) forms of leukotriene B(4) omega-hydroxylase. J. Biol. Chem. 274 (1999) 21191-21199
28. Christmas P., Jones J.P., Patten C.J., Rock D.A., Zheng Y., Cheng S.M., Weber B.M., Carlesso N., Scadden D.T., Rettie A.E., and Soberman R.J. Alternative splicing determines the function of CYP4F3 by switching substrate specificity. J. Biol. Chem. 276 (2001) 38166-38172
29. Shak S., and Goldstein I.M. Carbon monoxide inhibits omega-oxidation of leukotriene B4 by human polymorphonuclear leukocytes: evidence that catabolism of leukotriene B4 is mediated by a cytochrome P-450 enzyme. Biochem. Biophys. Res. Commun. 123 (1984) 475-481
30. Christmas P., Carlesso N., Shang H., Cheng S.M., Weber B.M., Preffer F.I., Scadden D.T., and Soberman R.J. Myeloid expression of cytochrome P450 4F3 is determined by a lineage-specific alternative promoter. J. Biol. Chem. 278 (2003) 25133-25142
31. Kikuta Y., Kusunose E., Kondo T., Yamamoto S., Kinoshita H., and Kusunose M. Cloning and expression of a novel form of leukotriene B4 omega-hydroxylase from human liver. FEBS Lett. 348 (1994) 70-74
32. Powell P.K., Wolf I., and Lasker J.M. Identification of CYP4A11 as the major lauric acid omega-hydroxylase in human liver microsomes. Arch. Biochem. Biophys. 335 (1996) 219-226
33. Johnson E.F., Hsu M.H., Savas U., and Griffin K.J. Regulation of P450 4A expression by peroxisome proliferator activated receptors. Toxicology (2002) 203-206